|
gptkbp:instance_of
|
gptkb:medical_devices
|
|
gptkbp:administered_by
|
transdermal route
|
|
gptkbp:administration_site
|
gptkb:Skin
|
|
gptkbp:approves
|
gptkb:2019
gptkb:FDA
|
|
gptkbp:clinical_trial
|
gptkb:DBV_Technologies
gptkb:Europe
gptkb:Australia
gptkb:North_America
over 500
Phase II
Phase III
randomized controlled trial
positive efficacy
PEPITES study
improved tolerance
|
|
gptkbp:collaborations
|
academic institutions
|
|
gptkbp:delivers
|
peanut protein
|
|
gptkbp:developed_by
|
gptkb:DBV_Technologies
|
|
gptkbp:duration
|
up to 3 years
|
|
gptkbp:duration_of_treatment
|
up to 12 months
|
|
gptkbp:feedback
|
generally positive
|
|
gptkbp:financial_support
|
available through programs
|
|
gptkbp:formulation
|
gptkb:patches
|
|
gptkbp:founded_in
|
gptkb:2002
|
|
gptkbp:funding
|
gptkb:venture_capital
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Viaskin Egg
|
|
gptkbp:ingredients
|
peanut protein extract
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_monitored_by
|
regular follow-ups
during treatment period
|
|
gptkbp:label
|
contains peanut protein
|
|
gptkbp:market_launch
|
gptkb:2020
|
|
gptkbp:marketed_as
|
multiple countries
|
|
gptkbp:mechanism_of_action
|
desensitization to allergens
|
|
gptkbp:patient_education
|
important for success
|
|
gptkbp:patient_population
|
peanut allergic patients
|
|
gptkbp:product
|
ongoing research
|
|
gptkbp:provides_guidance_on
|
developed by experts
available through prescription
|
|
gptkbp:publication
|
peer-reviewed journals
|
|
gptkbp:recruitment
|
diagnosed peanut allergy
|
|
gptkbp:regulatory_compliance
|
gptkb:European_Medicines_Agency
|
|
gptkbp:research_focus
|
gptkb:immunotherapy
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:service_frequency
|
daily
|
|
gptkbp:side_effect
|
skin irritation
reported in trials
|
|
gptkbp:target_allergen
|
peanuts
|
|
gptkbp:target_audience
|
children and adolescents
|
|
gptkbp:treatment
|
ongoing studies
evaluated in studies
long-term management
biologic therapy
gradual exposure
measured by food challenges
reduce allergic reactions
reduced severity of reactions
|
|
gptkbp:treatment_approval
|
based on clinical evidence
|
|
gptkbp:treatment_compliance
|
monitored through diaries
|
|
gptkbp:treatment_innovation
|
transdermal delivery system
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:used_for
|
treatment of peanut allergy
|
|
gptkbp:bfsParent
|
gptkb:DBV_Technologies
|
|
gptkbp:bfsLayer
|
8
|